Personalized Medicine News and Research

RSS

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.

8 May 2013

Expert to explain how drugs induce damage to DNA in public lecture on May 16

Anticancer drugs save lives and/or improve the quality of life for many cancer patients. Many anti-cancer drugs work by killing tumor cells after inducing damage to DNA.

4 May 2013

Cancer Genetics introduces proprietary urogenital cancer array for diagnosing kidney cancer

Cancer Genetics, Inc., a leader in oncology-focused personalized medicine, has launched a proprietary urogenital cancer array, UroGenRA, intended for kidney cancer diagnosis and subtyping in its own laboratory.

3 May 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

Oregon Health & Science University and Intel Corp. are teaming up to develop next-generation computing technologies that advance the field of personalized medicine by dramatically increasing the speed, precision and cost-effectiveness of analyzing a patient's individual genetic profile.

23 Apr 2013

HUGO recognizes Dr. Patrick Tan for research on genomic profiles of Asian cancers

Dr Patrick Tan from A*STAR's Genome Institute of Singapore has received the 2013 Chen New Investigator Award from the international Human Genome Organisation.

19 Apr 2013

Albert Einstein College of Medicine joins New York Genome Center

Albert Einstein College of Medicine of Yeshiva University will join the New York Genome Center (NYGC) as its twelfth Institutional Founding Member.

17 Apr 2013

High court seems skeptical that biotech firm can patent human genes

Supreme Court justices seemed to express skepticism Monday that a biotech company can patent human genes isolated from the body that signal a greater likelihood of ovarian or breast cancer.

17 Apr 2013

UCLA researchers classify kidney cancer into several unique subtypes

Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine.

17 Apr 2013

Researchers discover 14 new genetic variations associated with heart rate

Through a collaborative genome-wide study on individuals, researchers have discovered 14 new genetic variations that are associated with heart rate.

15 Apr 2013

FDA lengthens review periods for IVD tests that utilize molecular biomarkers

FDA review periods are lengthening for IVD tests that utilize molecular biomarkers, and at a faster rate than for IVDs overall, one of the key findings in a new report published this month by Amplion Research.

11 Apr 2013

Improvement in application of health information technology needed for better patient care

The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.

11 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Multiple genes strongly contribute to risk for schizophrenia

Multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity, according to an international study led by Virginia Commonwealth University School of Pharmacy researchers.

10 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

NanoVelcro chip device can help identify cancerous cells for treating prostate cancer

A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, have enhanced a device they developed to identify and "grab" circulating tumor cells, or CTCs, that break away from cancers and enter the blood, often leading to the spread of cancer to other parts of the body.

2 Apr 2013

Study raises alarm over loss of individual 'genomic liberty' due to gene patents

Humans don't "own" their own genes, the cellular chemicsals that define who they are and what diseases they might be at risk for. Through more than 40,000 patents on DNA molecules, companies have essentially claimed the entire human genome for profit, report two researchers who analyzed the patents on human DNA. Their study, published March 25 in the journal Genome Medicine, raises an alarm about the loss of individual "genomic liberty."

27 Mar 2013

Biological markers for triple-negative breast cancer (TNBC): an interview with Alexandre Templier, CEO of Quinten

Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.

27 Mar 2013

CHOP researchers moving closer to personalized medicine for children with cancer

Pediatric researchers, investigating the biology of brain tumors in children, are finding that crucial differences in how the same gene is mutated may call for different treatments.

27 Mar 2013

Personalized Medicine News and Research

Study shows patient selection based on biosamples makes clinical trials more efficient, reduces costs

Expert to explain how drugs induce damage to DNA in public lecture on May 16

Cancer Genetics introduces proprietary urogenital cancer array for diagnosing kidney cancer

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

HUGO recognizes Dr. Patrick Tan for research on genomic profiles of Asian cancers

Albert Einstein College of Medicine joins New York Genome Center

High court seems skeptical that biotech firm can patent human genes

UCLA researchers classify kidney cancer into several unique subtypes

Researchers discover 14 new genetic variations associated with heart rate

FDA lengthens review periods for IVD tests that utilize molecular biomarkers

Improvement in application of health information technology needed for better patient care

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Multiple genes strongly contribute to risk for schizophrenia

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

NanoVelcro chip device can help identify cancerous cells for treating prostate cancer

Study raises alarm over loss of individual 'genomic liberty' due to gene patents

Biological markers for triple-negative breast cancer (TNBC): an interview with Alexandre Templier, CEO of Quinten

CHOP researchers moving closer to personalized medicine for children with cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News